Teams AI Agent Takes a New Step Toward Alzheimer’s Treatment

A Teams AI agent is being evaluated to support Alzheimer’s treatment referrals by improving clinical workflow efficiency.

A new Teams AI agent for Alzheimer’s treatment is being developed by researchers at Vanderbilt University Medical Center (VUMC) to help doctors identify patients who may be eligible for disease-modifying Alzheimer’s therapies and streamline referrals to specialist care.

The 18-month research and implementation project, supported by a $600,000 grant from Eli Lilly and Company, will analyze healthcare data from more than 5,300 patients to identify delays in the Alzheimer’s treatment pathway and evaluate whether an AI-assisted workflow can improve referral efficiency. The Teams AI agent is currently under development and evaluation, and researchers have not yet demonstrated that it improves referral times, treatment access, or patient outcomes (1^✔ ✔Trusted Source
Team’s AI agent to speed Alzheimer’s treatment

Go to source

).

Why Is a Teams AI Agent Being Developed for Alzheimer’s Treatment?

Modern Alzheimer’s disease treatments require patients to undergo several clinical assessments before therapy can begin. People who may qualify for disease-modifying therapies often need cognitive testing, specialist evaluation, brain imaging, laboratory investigations, and confirmation that they meet treatment eligibility criteria. These multiple steps can create delays, especially in busy healthcare systems with growing numbers of patients.

To help address this challenge, VUMC researchers are developing a Teams AI agent that works within the hospital’s electronic health record (EHR) and Microsoft Teams platform. The goal is to organize referral information, identify patients who may require specialist evaluation, and simplify communication between healthcare professionals without changing how doctors make clinical decisions.

How Will the Teams AI Agent Support Doctors?

The AI system is designed as a clinical workflow assistant, not a diagnostic tool. It reviews information already available in a patient’s electronic health record, summarizes relevant clinical details, identifies missing referral information, and helps clinicians prepare referrals more efficiently. Doctors will continue to review every recommendation and remain fully responsible for diagnosis, treatment decisions, and patient care.

Because the tool is being developed within software that clinicians already use every day, researchers believe it could fit naturally into existing hospital workflows if future evaluation demonstrates that it is effective.

Project Overview: Teams AI Agent for Alzheimer’s Treatment

Researchers will first study existing referral pathways to identify common causes of delay before evaluating whether the AI system can improve workflow efficiency. The project focuses on supporting clinicians rather than replacing their expertise (1^✔ ✔Trusted Source
Team’s AI agent to speed Alzheimer’s treatment

Go to source).

Why the Teams AI Agent Is Still Under Evaluation

It is important to understand that this is an ongoing research and implementation project, not a completed clinical trial. The Teams AI agent is still being developed and evaluated, and researchers have not reported evidence showing that it reduces referral times, increases access to Alzheimer’s treatment, or improves patient outcomes (1^✔ ✔Trusted Source
Team’s AI agent to speed Alzheimer’s treatment

Go to source

).

Future evaluation during the 18-month project will determine whether the technology performs as intended in real-world clinical practice. The findings will also help researchers understand how AI can be integrated safely into healthcare systems while maintaining patient privacy, data security, and physician oversight.

What This Could Mean for Future Alzheimer’s Treatment

If future research confirms that the Teams AI agent improves referral workflows, it could help healthcare teams identify eligible patients more efficiently and reduce administrative burden without replacing clinical judgment. Faster coordination may eventually make it easier for patients to reach specialist care and complete the assessments required before treatment can begin.

For now, patients and caregivers should understand that the technology remains under study and is not yet part of routine Alzheimer’s care. The project represents an encouraging step toward using artificial intelligence to support healthcare professionals, but further evaluation is essential before its benefits can be confirmed. As research progresses, innovations like this may help build a more efficient, coordinated, and patient-centered approach to Alzheimer’s care while keeping physicians at the heart of every medical decision.

Why This Research Matters

The development of a Teams AI agent highlights how artificial intelligence could help simplify complex healthcare workflows for Alzheimer’s disease in the future. By supporting clinicians with referral coordination and clinical documentation, the technology aims to reduce administrative burden while allowing doctors to focus more on patient care. However, it is important to remember that the AI system is still under development and evaluation, and researchers have not yet demonstrated that it reduces referral delays, increases access to treatment, or improves patient outcomes (1^✔ ✔Trusted Source
Team’s AI agent to speed Alzheimer’s treatment

Go to source

).

If future evaluation confirms its effectiveness, the Teams AI agent could become a valuable clinical support tool for healthcare professionals managing patients with Alzheimer’s disease. Until then, people experiencing persistent memory or thinking problems should continue to seek timely medical evaluation through established healthcare services, as early assessment remains the best way to determine the cause of symptoms and discuss appropriate treatment options.

Reference:

1. Team’s AI agent to speed Alzheimer’s treatment – (https://news.vumc.org/2026/08/05/teams-ai-agent-to-speed-alzheimers-treatment/)

Source-Medindia